Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

Abstract Background Eligibility criteria are a critical part of clinical trials, as they define the patient population under investigation. Besides certain patient characteristics, clinical trials often include biomarker testing for eligibility. However, patient-identification mostly relies on the t...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Hanna Huebner, Christian M. Kurbacher, Geoffrey Kuesters, Andreas D. Hartkopf, Michael P. Lux, Jens Huober, Bernhard Volz, Florin-Andrei Taran, Friedrich Overkamp, Hans Tesch, Lothar Häberle, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Matthias Ruebner, Michael Untch, Peter A. Fasching, Wolfgang Janni, Tanja N. Fehm, Hans-Christian Kolberg, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss, Johannes Ettl
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2020-11-01
coleção:	BMC Cancer
Assuntos:	Advanced breast cancer Metastatic Antihormone therapy Heregulin Seribantumab MM-121
Acesso em linha:	http://link.springer.com/article/10.1186/s12885-020-07546-1
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!